In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA : An Encouraging Milestone to Further Clinical Drug Development

Ubah, ObinnaPorter, Andrew JBarelle, Caroline J2020-02-042020-02-042020-02-03Ubah, O, Porter, A J & Barelle, C J 2020, 'In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA : An Encouraging Milestone to Further Clinical Drug Development', Journal of Immunology Research, vol. 2020, 7283239, pp. 7283239. https://doi.org/10.1155/2020/72832392314-7156https://hdl.handle.net/2164/13655Funding Information: The authors wish to acknowledge the funding support for this work from Scottish Enterprise (SE) (VNAR_001 (2012)), the Biotechnology and Biological Sciences Research Council (BBSRC) (BB/K010905/1), and Innovate UK (102865).141506488engANTI-ADALIMUMAB ANTIBODIESTNF THERAPYINTERFERENCEMECHANISMSINFLIXIMABDISEASESR MedicineImmunology and AllergyImmunologyBiotechnology and Biological Sciences Research Council (BBSRC)BB/K010905/1RIn Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA : An Encouraging Milestone to Further Clinical Drug DevelopmentJournal article10.1155/2020/7283239http://www.scopus.com/inward/record.url?scp=85079741293&partnerID=8YFLogxK